A short-term follow-up CT based radiomics approach to predict response to immunotherapy in advanced non-small-cell lung cancer
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
A short-term follow-up CT based radiomics approach to predict response to immunotherapy in advanced non-small-cell lung cancer
Authors
Keywords
-
Journal
OncoImmunology
Volume 11, Issue 1, Pages -
Publisher
Informa UK Limited
Online
2022-01-25
DOI
10.1080/2162402x.2022.2028962
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Cancer statistics, 2020
- (2020) Rebecca L. Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- 18F-FDG Pet Parameters and Radiomics Features Analysis in Advanced Nsclc Treated with Immunotherapy as Predictors of Therapy Response and Survival
- (2020) Giulia Polverari et al. Cancers
- Dynamics of Serum Tumor Markers Can Serve as a Prognostic Biomarker for Chinese Advanced Non-small Cell Lung Cancer Patients Treated With Immune Checkpoint Inhibitors
- (2020) Zhibo Zhang et al. Frontiers in Immunology
- Predicting response to immunotherapy in advanced non-small-cell lung cancer using tumor mutational burden radiomic biomarker
- (2020) Bingxi He et al. Journal for ImmunoTherapy of Cancer
- Novel, non-invasive imaging approach to identify patients with advanced non-small cell lung cancer at risk of hyperprogressive disease with immune checkpoint blockade
- (2020) Pranjal Vaidya et al. Journal for ImmunoTherapy of Cancer
- Big data, big contributions: outcomes research in thoracic surgery
- (2019) Benjamin J. Resio et al. Journal of Thoracic Disease
- Comparing and contrasting predictive biomarkers for immunotherapy and targeted therapy of NSCLC
- (2019) D. Ross Camidge et al. Nature Reviews Clinical Oncology
- Predicting Response to Cancer Immunotherapy using Non-invasive Radiomic Biomarkers
- (2019) S Trebeschi et al. ANNALS OF ONCOLOGY
- Radiomics to predict response to immunotherapy, bridging the gap from proof of concept to clinical applicability?
- (2019) Eric Deutsch et al. ANNALS OF ONCOLOGY
- Comparison of RECIST, iRECIST, and PERCIST for the Evaluation of Response to PD-1/PD-L1 Blockade Therapy in Patients With Non–Small Cell Lung Cancer
- (2019) Lucian Beer et al. CLINICAL NUCLEAR MEDICINE
- PD-L1 Expression in Systemic Immune Cell Populations as a Potential Predictive Biomarker of Responses to PD-L1/PD-1 Blockade Therapy in Lung Cancer
- (2019) Ana Bocanegra et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial
- (2019) Tony S K Mok et al. LANCET
- Multi‐subtype classification model for non‐small cell lung cancer based on radiomics: SLS model
- (2019) Jian Liu et al. MEDICAL PHYSICS
- Automated image analysis of NSCLC biopsies to predict response to anti-PD-L1 therapy
- (2019) Sonja Althammer et al. Journal for ImmunoTherapy of Cancer
- Comparison of Biomarker Modalities for Predicting Response to PD-1/PD-L1 Checkpoint Blockade
- (2019) Steve Lu et al. JAMA Oncology
- Changes in CT Radiomic Features Associated with Lymphocyte Distribution Predict Overall Survival and Response to Immunotherapy in Non–Small Cell Lung Cancer
- (2019) Mohammadhadi Khorrami et al. Cancer Immunology Research
- PD-L1 Testing for Lung Cancer in 2019: Perspective From the IASLC Pathology Committee
- (2019) Sylvie Lantuejoul et al. Journal of Thoracic Oncology
- Stromal PD-L1–Positive Regulatory T cells and PD-1–Positive CD8-Positive T cells Define the Response of Different Subsets of Non–Small Cell Lung Cancer to PD-1/PD-L1 Blockade Immunotherapy
- (2018) Si-Pei Wu et al. Journal of Thoracic Oncology
- Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC
- (2018) Mark A. Socinski et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer
- (2018) Leena Gandhi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Association of the Lung Immune Prognostic Index With Immune Checkpoint Inhibitor Outcomes in Patients With Advanced Non–Small Cell Lung Cancer
- (2018) Laura Mezquita et al. JAMA Oncology
- A radiomics approach to assess tumour-infiltrating CD8 cells and response to anti-PD-1 or anti-PD-L1 immunotherapy: an imaging biomarker, retrospective multicohort study
- (2018) Roger Sun et al. LANCET ONCOLOGY
- Predictive Markers for the Efficacy of Anti–PD-1/PD-L1 Antibodies in Lung Cancer
- (2016) Takehito Shukuya et al. Journal of Thoracic Oncology
- Quantitative Assessment of the Heterogeneity of PD-L1 Expression in Non–Small-Cell Lung Cancer
- (2016) Joseph McLaughlin et al. JAMA Oncology
- Development of PD-1/PD-L1 Pathway in Tumor Immune Microenvironment and Treatment for Non-Small Cell Lung Cancer
- (2015) Jiabei He et al. Scientific Reports
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started